A new cohort study suggests that Medicaid expansion is associated with a lower mortality risk among patients with pancreatic ...

A triple drug approach that blocks the KRAS pathway at three points eliminated pancreatic tumors and prevented resistance in ...

A new preclinical study in mice shows that precancerous cells in the pancreas can be eliminated before they have the chance to become tumors. Using an experimental therapy to target microscopic ...

Candel Therapeutics Inc (NASDAQ:CADL) is advancing plans to bring its lead cancer immunotherapy toward potential ...

Cancer death rates in the UK have hit a record low, but the picture is more complicated than the headline figure suggests.

Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS inactivates RB1 via CDK4/6, while RB1 mutation is rare. Thus, CDK4/6 ...

Jean Trebek, Lisa Swayze, Joan Vassos, Stephen Nichols, Jeff Mauro, Jonathan Frakes, Kitty Swink, Rosa Blasi and Many More Raise [...] READ MORE ...

Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS inactivates RB1 via CDK4/6, while RB1 mutation is rare. Thus, CDK4/6 ...

Inform future clinical development plans, further establishing elraglusib as a potential backbone therapy in ...

For the first time in 30 years, there is a new FDA-approved treatment for locally advanced pancreatic cancer.

Cancer has traditionally been considered a disease that affects older adults, but recent observations suggest a concerning shift. Increasingly, more cases are being diagnosed in individuals under the ...

When dentist Dr Loo Yie Jin was told that his pancreatic cancer had spread to his liver, the news was devastating. He had already undergone surgery and ...